Robert Rottapel Selected Research

Cherubism

12/2016	Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2.
4/2015	Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.
12/2014	SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
9/2012	The 3BP2 adapter protein is required for chemoattractant-mediated neutrophil activation.
12/2011	Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.
12/2011	Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease.
8/2011	3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions.
4/2007	The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Rottapel Research Topics

Disease

23	Neoplasms (Cancer) 01/2022 - 06/2002
8	Cherubism 12/2016 - 04/2007
5	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 02/2012
4	Inflammation (Inflammations) 01/2022 - 06/2010
4	Breast Neoplasms (Breast Cancer) 01/2021 - 04/2014
3	Carcinogenesis 01/2022 - 03/2016
3	Carcinoma (Carcinomatosis) 11/2020 - 11/2019
2	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2020
2	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 08/2021
2	Ascites 01/2021 - 11/2019
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018 - 01/2017
2	Arthritis (Polyarthritis) 03/2015 - 01/2008
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2021
1	COVID-19 01/2021
1	Critical Illness (Critically Ill) 01/2021
1	Cysts 01/2021
1	Thrombosis (Thrombus) 01/2021
1	Respiratory Insufficiency (Respiratory Failure) 01/2021
1	Gout 12/2020
1	Alveolar Bone Loss 01/2020
1	Bone Resorption 01/2020
1	Periodontitis 01/2020
1	Chromosomal Instability (Chromosome Stability) 11/2019
1	Metabolic Bone Diseases (Osteopenia) 06/2017
1	Experimental Arthritis 03/2015
1	Inborn Genetic Diseases (Disease, Hereditary) 12/2014
1	Tics (Tic) 04/2014
1	Arthrogryposis renal dysfunction cholestasis syndrome 12/2011

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2002
5	TankyrasesIBA 01/2022 - 12/2011
5	Small Interfering RNA (siRNA)IBA 01/2022 - 02/2012
4	Phosphotransferases (Kinase)IBA 05/2020 - 07/2003
4	Carrier Proteins (Binding Protein)IBA 04/2015 - 08/2011
3	CytokinesIBA 01/2022 - 07/2010
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2014
3	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 08/2005
2	Immune Checkpoint InhibitorsIBA 08/2021 - 08/2020
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 01/2017
2	AutoantibodiesIBA 01/2021 - 03/2015
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 01/2021
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 04/2017
2	GuanineIBA 11/2019 - 01/2017
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2015 - 12/2014
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2022
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022
1	6-methyladenineIBA 01/2022
1	N-methyladenosineIBA 01/2022
1	Immunoglobulin M (IgM)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	RelaxinIBA 01/2021
1	Antiphospholipid AntibodiesIBA 01/2021
1	Uric Acid (Urate)IBA 12/2020
1	Colchicine FDA LinkGeneric 12/2020
1	Indicators and Reagents (Reagents)IBA 11/2020
1	Junctional Adhesion Molecule AIBA 11/2020
1	Fibronectins (Fibronectin)IBA 05/2020
1	tyrosine receptor (receptor, tyrosine)IBA 01/2020
1	Eph Family Receptors (Eph Receptors)IBA 01/2020
1	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA 01/2020
1	PlatinumIBA 11/2019
1	Alkylating AgentsIBA 11/2019
1	Platinum Compounds (Compounds, Platinum)IBA 11/2019
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2019
1	Proteasome Endopeptidase Complex (Proteasome)IBA 11/2019
1	Bortezomib (Velcade)FDA Link 11/2019
1	Proteasome InhibitorsIBA 11/2019
1	tremelimumabIBA 04/2019
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)IBA 01/2018
1	Monomeric GTP-Binding ProteinsIBA 01/2018
1	GTP Phosphohydrolases (GTPases)IBA 01/2018
1	NucleotidesIBA 01/2018
1	OsteocalcinIBA 06/2017
1	Glucose (Dextrose)FDA LinkGeneric 06/2017
1	Liposomes (Liposome)IBA 04/2017
1	Rho Guanine Nucleotide Exchange FactorsIBA 01/2017
1	TetraspaninsIBA 01/2017
1	MicroRNAs (MicroRNA)IBA 03/2016
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 03/2015
1	AntigensIBA 03/2015
1	Syk KinaseIBA 12/2014
1	Phospholipases (Phospholipase)IBA 12/2014
1	LigandsIBA 12/2014
1	Tartrate-Resistant Acid PhosphataseIBA 12/2014
1	Macrophage Colony-Stimulating FactorIBA 12/2014
1	CateninsIBA 10/2014
1	Mitogen-Activated Protein KinasesIBA 04/2014
1	Lapatinib (GW572016)FDA Link 04/2014
1	Pharmaceutical PreparationsIBA 04/2014
1	AntibodiesIBA 01/2014
1	platelet protein P47 (pleckstrin)IBA 09/2012
1	Complement System Proteins (Complement)IBA 02/2012
1	SolutionsIBA 12/2011
1	Peptides (Polypeptides)IBA 12/2011

Therapy/Procedure

4	Therapeutics 11/2020 - 04/2014
3	Immunotherapy 08/2021 - 04/2019
2	Drug Therapy (Chemotherapy) 11/2019 - 04/2014
1	Critical Care (Surgical Intensive Care) 01/2021
1	Ligation 01/2020